Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
10.1038/bcj.2011.43
Saved in:
Main Authors: | Hart, S., Goh, K.C., Novotny-Diermayr, V., Tan, Y.C., Madan, B., Amalini, C., Ong, L.C., Kheng, B., Cheong, A., Zhou, J., Chng, W.J., Wood, J.M. |
---|---|
Other Authors: | CANCER SCIENCE INSTITUTE OF SINGAPORE |
Format: | Article |
Published: |
2014
|
Subjects: | |
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/117115 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia
by: Ikezoe, T., et al.
Published: (2016) -
Dual mutations in the AML1 and FLT 3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype
by: Matsuno, N., et al.
Published: (2011) -
IDENTIFICATION AND CHARACTERIZATION OF NOVEL LONG NON-CODING RNAs IN ACUTE MYELOID LEUKEMIA
by: SRISHTI MISHRA
Published: (2023) -
Runx1 protects hematopoietic stem/progenitor cells from oncogenic insult
by: Motoda, L., et al.
Published: (2011) -
Runx1 protects hematopoietic stem/progenitor cells from oncogenic insult
by: Motoda, L., et al.
Published: (2012)